anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Many children with obstructive sleep apnea (OSA) are not identified and thus do not receive treatment. In a previous study, the investigators found that a clinical decision support system helped primary care providers (PCPs) identify children with obstructive sleep apnea (OSA). In this system, parents of children report on possible OSA symptoms (e.g., snoring, sleepiness) in their child before the visit. If the child has OSA symptoms, the PCP receives an alert during the visit recommending further evaluation and a possible referral for a sleep study or to see a specialist. While this system helped increase the number of children with OSA symptoms who received a referral, many children remained unidentified. The goal of this study is to see whether involving parents in the system can identify even more children.

In this study, the investigators propose to test the impact of a health communication message, designed to educate and activate parents about their child's risk for OSA. This message is an infographic that helps parents recognize nighttime symptoms of OSA and how these nighttime symptoms may be impacting their child during the day. If a child has OSA symptoms, parents would view this infographic before their child's PCP visit and could discuss OSA with their child's PCP. For children with OSA symptoms, their parents will be randomized to either: 1) view the health communication message, or; 2) usual care, in which parents are not given any additional information about OSA or their child's risk prior to the appointment. In both cases, PCPs will receive a prompt indicating that the child is at risk for OSA.
An adapted therapeutic exercise program using blood flow restriction cuff perfomed during chemotherapy treatment. 24-36 sessions of 1 hour multimodal components: aerobic, strength and fascial release exercises. Frequency will be adapted to the recovery status of each patient.
One-third of the global population is affected by anemia making it one of the major public health problems at the global level. Women of reproductive age are at risk for anemia. The prevalence of anemia reported in 2016 Ethiopian Demographic and Health Survey (EDHS) is a moderate public health problem at the national level, but it is a severe public health problem in the Somali regional state among women of reproductive age (WRA). The purpose of this study is to assess the etiology and determinant factors of anemia among women of reproductive age. A cross-sectional design will be employed for the current study. In the current study, the investigators will assess the causes and contributing factors for anemia and their relationship with anemia. Women of reproductive age 18-49 years old residing in the Kebribeyah district are the target population for this study. The sample size determined for the current study is 881. The Somali region was selected for the current study due to its highest prevalence of anemia (60.6%%) among women of reproductive age according to the EDHS 2016. Kerbribeyah district was selected from the Somali regional state. Simple random sampling was employed to select three kebeles (villages) from the available kebeles with no other nutrition interventions in the Kebribeyah district. Two enumerations areas (EAs) from each of the three kebeles will be selected by simple random sampling. The sample size determined will be allocated to three kebeles and two EAs within the Kebeles on probability proportional to size (PPS). The study participants will be selected by systematic random sampling from a list of participants in a sampling frame obtained by house-to-house listing. After obtaining written informed consent, the data will be collected from the selected participant in their homes. All study participants who take part in the current study will be interviewed. They will also provide blood, urine, and stool samples. The prevalence of anemia and iron status biomarkers are the primary outcomes for the current study. The participants will be tested for anemia by measuring hemoglobin concentration. In addition, a complete blood count (CBC) test will be done for all study participants. The current study will fill the evidence gap by identifying major causes and contributors to overall anemia among women of reproductive age in the Kebribeyah district. The researchers anticipate that determining the causes of anemia will be a crucial first step in tackling the high prevalence of anemia among women of reproductive age in the Somali regional state and beyond.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine and can be applied for reparation of meniscus rupture in individuals. From collagen membrane made is plate, which on one side has smooth barrier surface, preventing cell adhesion to it and preventing cell penetration through it, and where said plate has on the side, opposite to smooth barrier surface, fibrous surface, which allows cells to grow through it, where collagen is composed mainly of collagen I. Plate is fixed above meniscus rupture in such a way that its fibrous surface faces meniscus rupture. ^ EFFECT: method makes it possible to accelerate healing of meniscus rupture. ^ 18 cl, 1 ex, 3 dwg
This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Currently there is very little understanding as to how Barrett's esophagus develops and why some people with Barrett's esophagus go on to develop esophageal cancer. The purpose of this study is to develop a better understanding of how these processes occur. The investigators also hope to use the information from this study to identify new molecular markers that the investigators can use to better determine who will or will not go on to develop esophageal cancer. Patients who have been diagnosed in the past with Barrett's esophagus will be asked to participate. Patients without Barrett's esophagus will be asked to take part so that the investigators can compare tissue from patients without the conditions to those with the conditions.
The invention belongs to the field of traditional Chinese medicines, relates to an active ingredient with an anticomplementary effect in a natural medicine, and particularly relates to natural homogeneous polysaccharide in lithospermum and application thereof in preparing anticomplementary medicines; the invention separates two homogeneous polysaccharides APS-1 and APS-2 from lithospermum erythrorhizon, experiments prove that the homogeneous polysaccharides of lithospermum erythrorhizon have obvious inhibition effect on the classical pathway and the alternative pathway of complement activation, wherein the polysaccharide APS-1 of lithospermum erythrorhizon has the CH inhibition effect on the classical pathway and the alternative pathway of the complement system 50 And AP 50 The values are 203 +/-20 mu g/ml and 45 +/-8 mu g/ml respectively; the lithospermum polysaccharide APS-2 has CH inhibiting effect on the classical pathway and the alternative pathway of the complement system 50 And AP 50 The values were 282. + -. 11. mu.g/ml and 144. + -. 17. mu.g/ml, respectively. The natural homogeneous polysaccharide in the lithospermum can be further used as an active ingredient to prepare novel anticomplement medicines.
Disclosed are hair and body cleansers containing 0.05 to 40 wt. % of surfactant(s), 0.0001 to 5 wt. % of fragrance(s), and 0.1 to 10 wt. % of spherical porous polyamide particles, the percentages being in relation to the weight of the entire composition. The spherical porous polyamide particles have a number average particle diameter ranging from 1 to 30 μm, a minimum specific surface area of 5 m²/g according to BET (DIN 66131), a minimum oil absorption capacity (boiled linseed oil) of 200 ml/100 g, a minimum crystallinity (DSC measurement) of 40 percent, and a ratio between the volume average particle diameter and the number average particle diameter ranging from 1.0 to 1.5. Said particles provide a long lasting scent, absorb unpleasant odors, and increase the performance profile and the persistence of the scented impression.
Pulmonary hypertension (PH) is a chronic and progressive disorder characterized by elevated mean pulmonary arterial pressure, pulmonary vascular remodeling, and the development of concentric laminar intimal fibrosis with plexiform lesions. While rodent models have been developed to study PH, they have certain deficiencies and do not entirely replicate the human disease due to the heterogeneity of PH pathology. Therefore, combined models are necessary to study PH. Recent studies have shown that altered pulmonary blood flow is a significant trigger in the development of vascular remodeling and neointimal lesions. One of the most promising rodent models for increased pulmonary flow is the combination of unilateral left pneumonectomy with a "second hit" of monocrotaline (MCT) or SU5416. The removal of one lung in this model forces blood to circulate only in the other lung and induces increased and turbulent pulmonary blood flow. This increased vascular flow leads to progressive remodeling and occlusion of small pulmonary arteries. The second hit by MCT or SU5416 leads to endothelial cell dysfunction, resulting in severe PH and the development of plexiform arteriopathy.
We report a rare case of intramedullary spinal cord malakoplakia mimicking malignancy on 18F-FDG PET/CT. A 61-year-old man underwent a contrast-enhanced spinal cord MRI to evaluate 1 week of progressive left-sided weakness. Spinal cord MRI showed a 1.3-cm enhancing intramedullary cervical spinal cord mass at C5 level with cord edema. Subsequently, 18F-FDG PET/CT was performed for evaluation. The images showed a well-circumscribed hypermetabolic mass in the spinal cord; no lesions were suggestive of malignancy or metastasis. A subtotal tumor excision was performed; histopathological examination revealed malakoplakia. This emphasizes the significance of histopathological evaluation and the importance of diagnostic confirmation.
The propagation of a seizure wavefront in the cortex divides an intensely firing seizure core from a low-firing seizure penumbra. Seizure propagation is currently thought to generate strong activation of inhibition in the seizure penumbra that leads to its decreased neuronal firing. However, the direct measurement of neuronal excitability during seizures has been difficult to perform in vivo. We used simultaneous optogenetics and calcium imaging (all-optical interrogation) to characterize real-time neuronal excitability in an acute mouse model of seizure propagation. We find that single-neuron excitability is decreased in close proximity to the seizure wavefront but becomes increased distal to the seizure wavefront. This suggests that inhibitory neurons of the seizure wavefront create a proximal circumference of hypoexcitability but do not influence neuronal excitability in the penumbra.
FIELD: pharmacy. SUBSTANCE: invention relates to the improved oral pharmaceutical medicinal forms of high dosage of an active substance. An active substance is mycophenolatemophetyl, mycophenolic acid or ranolazine. Indicated active substance is in a liquid state obtained by its heating to the point above its melting point followed by cooling to the point below its melting point. In preferable variant the oral pharmaceutical medicinal form is made as a capsule and contains therapeutically effective amount of mycophenolatemophetyl in liquid state obtained by heating to the first temperature above 95 C followed by cooling to the second temperature below 80 C. EFFECT: improved indices of availability of an active substance, decreased daily doses of drug intake by patients. 19 cl, 6 ex
FIELD: medicinal plant preparations. SUBSTANCE: method involves the extraction of milled ergots with acid aqueous acetone solution, extract evaporation, pH change to alkaline value and extraction with chloroform. After evaporation of chloroform extract and residue filtration through aluminium oxide technical sum of ergot alkaloids is obtained. The yield of the end product at extraction stage is increased by 16% as compared with prototype. EFFECT: increased yield of product. 2 cl, 2 tbl
Curcumin is a chemical compound of the curcuminoids class found in the root of Curcuma (Curcuma longa), and due to its potential antioxidant and anti-inflammatory, has been suggested as a nutritional strategy to reduce oxidative stress and inflammation present in several chronic diseases. Although it is a promising therapy, there are no studies evaluating the effects of curcumin in patients with chronic kidney disease (CKD) in peritoneal dialysis (PD). The aim of this study is to evaluate the effect of curcumin supplementation on inflammatory markers and oxidative stress in patients with CKD in PD. Methods: This is a longitudinal randomized clinical double-blind crossover study, with a washout period and placebo-controlled, where patients will be randomized into two groups: Turmeric and Placebo. After the 12-week supplementation period, a washout (12 weeks) will be performed for subsequent crossover of the patients. Mononuclear cells will be extracted from whole blood and the expression of m ribonucleic acid from transcription factors (Nrf2 and NF-kB), antioxidant enzymes (NQO1, HO-1), as well as NLRP3 inflammasome will be analyzed by real-time Polymerase Chain Reaction and protein expression by western blotting. Inflammatory cytokine levels will be assessed by ELISA, also, plasma levels of TBARS, routine laboratory parameters, as well as food intake and nutritional status.
Inflammation is an essential immune response critical for responding to infection, injury and maintenance of tissue homeostasis. Upon injury, regenerative inflammation promotes tissue repair by a timed and coordinated infiltration of diverse cell types and the secretion of growth factors, cytokines and lipids mediators. Remarkably, throughout evolution as well as mammalian development, this type of physiological inflammation is highly associated with immunosuppression. For instance, regenerative inflammation is the consequence of an in situ macrophage polarization resulting in a transition from pro-inflammatory to anti-inflammatory/pro-regenerative response. Immune cells are the first responders upon injury, infiltrating the damaged tissue and initiating a pro-inflammatory response depleting cell debris and necrotic cells. After phagocytosis, macrophages undergo multiple coordinated metabolic and transcriptional changes allowing the transition and dictating the initiation of the regenerative phase. Differences between a highly efficient, complete ad integrum tissue repair, such as, acute skeletal muscle injury, and insufficient regenerative inflammation, as the one developing in Duchenne Muscular Dystrophy (DMD), highlight the importance of a coordinated response orchestrated by immune cells. During regenerative inflammation, these cells interact with others and alter the niche, affecting the character of inflammation itself and, therefore, the progression of tissue repair. Comparing acute muscle injury and chronic inflammation in DMD, we review how the same cells and molecules in different numbers, concentration and timing contribute to very different outcomes. Thus, it is important to understand and identify the distinct functions and secreted molecules of macrophages, and potentially other immune cells, during tissue repair, and the contributors to the macrophage switch leveraging this knowledge in treating diseases.
Formulation 609580 20 cream is applied topically to the entire body twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609209 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
INTRODUCTION: Cancer-related pain is ubiquitous. Targeted procedural interventions may be an important and underutilized method for improving cancer-related pain and quality of life. The goal of this study was to determine the baseline educational experience and perceived post-graduation comfort of Pain Medicine fellows in performing procedures that can be used for cancer-related pain.
METHODS: Using Qualtrics, a 16-question survey was distributed to graduating fellows at accredited Pain Medicine Fellowship programs in the USA in June 2022. The fellows' experience and comfort level performing eight procedures was analyzed using summary descriptive statistics and contingency table analysis with statistical significance determined by Pearson's χ2 test.
RESULTS: Survey respondents represented 30% of fellows among 44% of Pain Medicine programs during the 2021-2022 academic year. The majority of respondents reported no experience performing 7 of the 8 procedures for cancer-related pain (56.1%-90.6%). Graduating fellows reported overall comfort performing sympathetic neurolysis (65.7%), spinal cord stimulator trials (85.7%) and implantations (66.0%), but not intrathecal pump trials (36.9%) and implantations (31.3%), peripheral nerve stimulator implantations (41.7%), vertebral augmentations (31.3%), and vertebral body radiofrequency ablations (16.7%).
CONCLUSIONS: Experience performing 10 or more of the surveyed procedures, personal interest in treating cancer-related pain, and attendance of cancer-related pain lectures were found to significantly increase comfortability in performing cancer-related pain procedures post graduation, whereas cadaver-based learning did not. This study highlights the need for more robust procedural education for cancer-related pain and identifies procedural experience in non-cancer patients and lectures on cancer-related pain as ways to bridge this educational gap.
The invention provides a respiratory syncytial virus adenovirus vector vaccine, a preparation method and application thereof, in particular to an adenovirus vector suitable for a mucous membrane administration preparation aiming at RSV (respiratory syncytial virus) is screened from a plurality of adenovirus vectors. Inoculation is carried out by inhalation, the infection process of the virus is simulated, and immune response is stimulated. Can avoid local adverse reactions such as injection part pain and the like caused by intramuscular injection. By inhalation to the lung, the atomized vaccine can finally reach the lung through the respiratory tract, and the humoral immunity and the cellular immunity are generated, and meanwhile, the respiratory tract mucosal immunity is stimulated, wherein the lung mucosal immunity is the most effective method for preventing RSV infection and transmission. While stimulating the mucosal immunity of the lung, it also exhibits better humoral immunity levels. The invention screens the inhaled dose, the dose used is smaller than the intramuscular injection dosage form, and the safety is improved.
1419969 Immunostimulating agent INSTITUT PASTEUR 21 Dec 1972 [24 Dec 1971] 59164/72 Heading A5B A pharmaceutical composition comprises (a) an immunostimulating agent obtained by: (i) extracting cells selected from splenic cells, Ehrlich ascite cells, bacterial cells and Saccharomyces cerevisiae, cells with a solvent mixture comprising a halogenated hydrocarbon and an alcohol, (ii) separating the insoluble residue from the liquid extract, (iii) evaporating the liquid extract to obtain a solid residue, (iv) extracting the solid residue with chloroform to obtain a chloroform solution of said immunostimulating agent and (v) separating this chloroform solution from any undissolved solid residue and (b) a pharmaceutically acceptable carrier. The splenic cells may be mice splenic cells which optionally have been infected with Listeria monocytogenes bacteria. The bacterial cells used to prepare the extract may be cells of Listeria monocytogenes, Salmonella typhimurium, Escheria coli, Corynebacterium parvum, Mycobacterium tuberculosis, Vibrio cholera, Bacillus subtilis. The extraction solvent mixture may be chloroform and methanol. The pharmaceutically acceptable carrier may be an injectable liquid carrier, e.g. saline. A saline dispersion is prepared by dispersing the chloroform solution in saline, bubbling a gas through the dispersion to evaporate the chloroform and homogenising the resulting dispersion. As an alternative to the injectable solution, the immunostimulating agent can be incorporated in a calcium phosphate gel.
Patients (over the age of 18) who will be undergoing surgery for hip fracture repair. These patients will receive an ultrasound of the heart and lungs to determine whether or not information gained from this ultrasound assessment is significant enough to influence their anesthetic care plan.
OBJECTIVE: Remimazolam, a novel benzodiazepine, is widely used as an anesthetic in endoscopic procedures; however, its effects on cognitive function remain unclear, limiting its broader application in general anaesthesia. Neuroinflammation is a well-established key factor in the etiology and progression of cognitive dysfunction, including conditions such as Alzheimer's disease, Parkinson's disease, postoperative delirium, and postoperative cognitive dysfunction. Preclinical studies have demonstrated that remimazolam exerts anti-inflammatory and neuroprotective effects, and clinical reports indicate a reduced incidence of postoperative delirium in patients treated with remimazolam. Nevertheless, whether remimazolam improves cognitive function through its anti-inflammatory properties remains uncertain. This study aimed to investigate the neuroprotective effects of remimazolam and its underlying mechanism in a lipopolysaccharide (LPS)-induced model of neuroinflammation, neuronal injury, and cognitive dysfunction METHODS: C57BL/6 J male mice were administered LPS intraperitoneally to establish a model of neuroinflammation-induced cognitive impairment. A subset of mice received remimazolam via intraperitoneal injection 30 minutes prior to LPS administration. Cognitive performance was evaluated using behavioural tests, including the Morris Water Maze (MWM), Novel Object Recognition (NOR) test, and Open Field Test (OFT). Hippocampal tissues were analyzed by haematoxylin-eosin (HE) staining to assess structural changes. Inflammatory markers, including Interleukin (IL)-6, IL-1β, and tumor necrosis factor-α, were quantified using enzyme-linked immunosorbent assay (ELISA) and real-time quantitative PCR. Immunofluorescence was used to detect translocator protein (TSPO) and markers of microglia activation (IBA-1, CD16/32, and CD206).
RESULTS: (1) Remimazolam reversed LPS-induced cognitive deficits, as evidenced by shorter spatial exploration latency and increased platform crossings in the MWM, and an elevated recognition index in the NOR test. (2) Remimazolam improved hippocampal morphology, reducing LPS-induced neuronal damage. (3) Remimazolam significantly decreased levels of hippocampal inflammatory cytokines, inhibited microglial activation, promoted M2-type microglia polarization, and increased TSPO expression.
CONCLUSION: Remimazolam demonstrated neuroprotective and anti-neuroinflammatory effects in a mouse model of LPS-induced cognitive impairment. These effects are likely mediated through the regulation of TSPO, which inhibits microglial activation and promotes the polarization of microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype.
Patients will be randomised to treatment with placebo (n=87). Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
Study arm will consume a Mediterranean like diet, while tracking their food intake for 9 weeks. With low MEdDIet score.